Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
12 min read
Lamellar Ichthyosis, Autosomal Dominant Form Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Lamellar Ichthyosis, Autosomal in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Latest Hotspot
12 min read
Renal Tubular Acidosis, Distal, Autosomal Recessive Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Renal Tubular Acidosis in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Neutropenia, Severe Congenital, Autosomal Recessive 4 Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Neutropenia, Severe in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Agenesis of Corpus Callosum Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Agenesis of Corpus Callosum in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Latest Hotspot
12 min read
Keratitis, Ichthyosis, and Deafness (KID) Syndrome Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Keratitis, Ichthyosis, and in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Latest Hotspot
12 min read
Osteopetrosis Autosomal Dominant Type 2 Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Osteopetrosis Autosomal in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Spastic Ataxia Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Spastic Ataxia with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Bile Acid Synthesis Defect, Congenital, 1 Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Bile Acid Synthesis Defect in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Latest Hotspot
12 min read
Osteopetrosis, Autosomal Recessive 1 Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Osteopetrosis, Autosomal in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Non-squamous non-small cell lung cancer Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Non-squamous non-small cell in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Latest Hotspot
12 min read
Polyendocrinopathies, Autoimmune Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Polyendocrinopathies in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Myopathies, Nemaline Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Myopathies, Nemaline with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..